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Introduction
The granulocyte-specific Ca2+-binding protein S100A12 is
overexpressed during autoinflammation as well as other
inflammatory conditions in humans and has been ascribed
to the group of pro-inflammatory Damage Associated
Molecular Pattern molecules (DAMPs). S100A12-levels in
human serum reveal excellent correlation with patients’
inflammation state, which renders S100A12 a powerful
biomarker. In order to operate as DAMP S100A12
requires binding to cellular receptors. The protein was ori-
ginally found to bind RAGE and was in turn entitled
extracellular newly identified RAGE-binding protein (EN-
RAGE). RAGE ligation by S100A12 is proposed to trigger
a pro-inflammatory cascade in microvascular endothelial
cells, macrophages and lymphocytes, culminating in NF-
B activation. This amplifies the inflammatory response by
triggering further RAGE expression and thus drives a
feed-forward loop that can potentiate inflammation.
Objectives
RAGE-binding by S100A12 can still be discussed contro-
versial and an alternate receptor for S100A12 on mono-
nuclear cells is suggested. Based on the previous
discovery of S100A8/A9 signalling through TLR4 we stu-
died the relevance of this particular pathway for S100A12
as alternative to the originally postulated signaling
through RAGE.
Methods
The release of human S100A12 from granulocytes as well
as the promotion of inflammation by activation of
human monocytes after specific receptor-interaction was
investigated by a series of in vitro experiments on
primary cells and receptor-expressing cell lines.
Results
Upon inflammatory challenge S100A12 expression from
human granulocytes is rapidly induced in vitro and in vivo.
The protein is both passively released from necrotic cells
and secreted via alternative secretory pathways. A global
gene expression analysis of S100A12-activated monocytes
revealed that human S100A12 induces strong inflamma-
tory responses. These can be abrogated by specifically
blocking toll-like receptor 4 (TLR4) on primary human
monocytes as well as TLR4-overexpressing HEK-TCM
cells. On the contrary, blocking S100A12 binding to
RAGE reveals no such pronounced effect on both mono-
cytes and RAGE-overexpressing cell lines. Importantly, as
the observed effects on human monocytes appear to be
TLR4-dependent, the S100A12-induced gene expressing
pattern differed in part significantly from that induced by
the primary TLR4 ligand LPS.
Conclusion
We identified human S100A12 as an endogenous TLR4
ligand that induces a unique pro-inflammatory gene
expression signature resulting in monocyte activation.
Beyond the well-documented implication of S100A12 as
inflammatory biomarker, our data shed new light on the
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